Sign In
Buy PHRRF
$0.0470
+0.0004 (+0.772%)
At Close: Jun 03, 2026
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022
07:00am, Monday, 13'th Sep 2021
TORONTO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to pr
PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference
08:51am, Thursday, 09'th Sep 2021
TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to an
PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021
05:37pm, Tuesday, 07'th Sep 2021
TORONTO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released b
PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's Disease
08:05am, Tuesday, 25'th May 2021
TORONTO, May 25, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to anno
Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher's Ketamine Programs
09:28am, Thursday, 20'th May 2021
TORONTO, May 20, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a psychedelics biotech company, is pleased to announce the appoin
PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's Disease
07:59am, Monday, 17'th May 2021
TORONTO, May 17, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a psychedelics biotech company, is pleased to announce that the U
Newscope Announces Name Change to PharmaTher Holdings Ltd.
11:29am, Tuesday, 13'th Apr 2021
TORONTO, April 13, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company”) (CSE: PHRM) (OTCQB: PHRRF) is pleased to announce that, further to the news release dated April 8, 2021, it
Newscope Announces Name Change
10:40am, Thursday, 08'th Apr 2021
TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company”) (CSE: PHRM) (OTCQB: PHRRF) is pleased to announce that it has filed an alteration notice with BC Registry S
Newscope Capital Provides Dial-In Information for Special Meeting
02:01pm, Thursday, 01'st Apr 2021
TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company”) (CSE: PHRM) (OTCQB: PHRRF) would like to provide the following dial-in information for the Company's upcomi
PharmaTher Advancing Research for Novel Microneedle Delivery of Ketamine
07:00am, Wednesday, 24'th Mar 2021
Represents a potential next-generation treatment for neuropsychiatric, neurodegenerative and pain disorders TORONTO, March 24, 2021 /PRNewswire/ - Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRR
World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor
09:15am, Tuesday, 16'th Mar 2021
Dr. Fava to advise on the clinical development of KETABET™ for Major Depressive Disorder Dr. Fava to advise on the clinical development of KETABET™ for Major Depressive Disorder
PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig's Disease
07:00am, Tuesday, 02'nd Mar 2021
TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sc
Newscope Announces DTC Eligibility of Its Common Shares in the United States
07:57am, Monday, 01'st Mar 2021
TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company” or “Newscope”) (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“
PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals
07:00am, Tuesday, 23'rd Feb 2021
TORONTO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sci
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine
07:59am, Monday, 01'st Feb 2021
TORONTO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sci
